Skip to main content
. 2016 Jul 13;7(35):56153–56169. doi: 10.18632/oncotarget.10593

Figure 7. BRG1 is Silenced by the PI3K/AKT/mTOR Pathway at the Translational Level.

Figure 7

A. shows that the BRG1 mRNA levels only differ by about ~1.2 ΔCT value (equal to around a ~2.3-fold difference) in BRG1-positive and BRG1-negative (nonmutated) cell lines. B. BRG1 transfection into C33A, Panc1 and H1573 cells caused greater than 1000-fold induction of BRG1 mRNA relative to untransfected control. C. After BRG1 transfection into C33A, Panc1 and H1573 cell lines, BRG1 protein only marginally increased BRG1 untransfected is denoted by “-“ and BRG1 transfected cells are denoted by “+”. D. BRG1 induction was observed when Panc1, C33A and H1573 cells were treated with 5 uM of the pan AKT inhibitor MK-2206 (MK), the dual PI3K/mTOR inhibitor BEZ235 (BEZ) or the PI3K inhibitor ZSTK474 (ZST) for 72 hours. “U” designates the test cell line: C33A, Panc1 or H1573 without drug treatment. GAPDH was used as the loading control. E. BRG1 mRNA only increased ~2-fold after treatment with MK2206, BEZ235 or ZST474 in the C33A, Panc1 and H1573 BRG1-deficient cell lines.